SCM Life Sciences Invited to 'JP Morgan Healthcare Conference'

Core Stem Cell Source Technology
Introduction to Major Therapeutic Clinical Outcomes Planned

[Asia Economy Reporter Lee Gwan-joo] SCM Lifescience announced on the 7th that it has been invited to the '2023 JP Morgan Healthcare Conference' to be held in San Francisco, USA, in January next year, where it plans to conduct business meetings with overseas pharmaceutical and bio companies focusing on its proprietary technology and the clinical results of three ongoing therapeutics.

At the concurrently held '2023 Biotech Showcase,' SCM Lifescience will present the results of the Phase 2a clinical trial for acute pancreatitis, which was recently announced at the Korean Digestive Disease Week (KDDW).

Additionally, SCM Lifescience has been selected as a presenting company at the side event '3rd Global IR @JPM,' where it will introduce its stem cell proprietary technology and the clinical outcomes of major stem cell therapeutics utilizing this technology to global investors. This event is jointly hosted by the Korea Bio Association, the U.S. biopharmaceutical magazine BioCentury, and the U.S.-based global law firm Sidley Austin LLP, with support from Nasdaq and the Ministry of Trade, Industry and Energy. Unlike previous editions held online, this event will be held offline for the first time. Six companies, including SCM Lifescience, were finally selected as presenting companies from Korea.

A representative from SCM Lifescience stated, "Through the world's largest pharmaceutical, bio, and healthcare conference and its side events, we plan to introduce our unique proprietary technology for stem cell isolation and cultivation, as well as the clinical results of key stem cell therapeutic pipelines such as acute pancreatitis, atopic dermatitis, and chronic graft-versus-host disease." They added, "We aim to establish networks with global pharmaceutical and bio companies and actively review and incorporate their feedback to create a concrete strategy for future technology transfers, global clinical trials, and market entry."